News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Subscribe To Our Newsletter & Stay Updated
